ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Neuroscience Clinical Development

Helix Launches Combined Clinical and Genomic Data for Disorders Related to Cardiovascular, Metabolic, Immunological, and Inflammatory Conditions

Saturday, June 08, 2024

Helix, a pioneer in population genomics, is rolling out new clinico-genomic datasets to enhance precision medicine in drug discovery and development. These cohorts, created through extensive collaborations with health systems, feature detailed longitudinal clinical and genomic data across multiple therapeutic areas, including Cardiovascular, Immunology & Inflammation, and Metabolic conditions.

Helix, noted, “Researchers in life sciences can use our diverse clinico-genomic cohorts to delve into the genetic factors that influence disease progression and clinical outcomes, and to validate potential therapeutic candidates.” He also mentioned, “Organizations can quickly pinpoint targeted patient groups based on specific genetic and phenotypic details, optimizing the discovery and development process.”

The precision cohorts from Helix combine longitudinal clinical data with proprietary Exome+® sequencing data from over 125,000 patients across the United States, all of whom have consented to be recontacted. Through regular updates, partners gain access to organized EHR fields, such as clinical diagnoses, medical procedures, lab results, and prescriptions. For instance, the Cardiometabolic cohort includes data from more than 50,000 patients diagnosed with significant Cardiovascular Diseases, including patient vitals, demographics, and essential lab results like triglycerides, HbA1c, and cholesterol. These data points are linked with exome sequencing data, covering important Cardiovascular genes like TTN, MYH7, and others.

Dr. James Lu, M.D., Ph.D., CEO and co-founder of Helix, commented, “As the field of precision therapies grows rapidly, clinico-genomic data offer tremendous opportunities to develop targeted treatments that are safer and more effective.” He added, “By utilizing real-world data and genomics, precision medicine can transform drug development, paving the way for a future of personalized, customized treatments.”

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific viral vector services (VVS)ThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva